Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
SpringWorks Therapeutics Inc is a biotechnology business based in the US. SpringWorks Therapeutics shares (SWTX) are listed on the NASDAQ and all prices are listed in US Dollars. SpringWorks Therapeutics employs 190 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $26.52 |
|---|---|
| 52-week range | $13.60 - $89.75 |
| 50-day moving average | $32.16 |
| 200-day moving average | $54.41 |
| Wall St. target price | $76.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.23 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $26.52 from 2022-07-01
| 1 week (2022-06-24) | 3.39% |
|---|---|
| 1 month (2022-06-03) | 22.83% |
| 3 months (2022-03-30) | N/A |
| 6 months (2021-12-30) | -57.45% |
| 1 year (2021-07-02) | -69.21% |
|---|---|
| 2 years (2020-07-02) | -34.60% |
| 3 years (2019-06-29) | N/A |
| 5 years (2017-06-29) | N/A |
| Revenue TTM | $35 million |
|---|---|
| Gross profit TTM | $35 million |
| Return on assets TTM | -26.71% |
| Return on equity TTM | -45.18% |
| Profit margin | 0% |
| Book value | $7.70 |
| Market capitalisation | $1.3 billion |
TTM: trailing 12 months
We're not expecting SpringWorks Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, SpringWorks Therapeutics's shares have ranged in value from as little as $13.6 up to $89.746. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SpringWorks Therapeutics's is 1.0756. This would suggest that SpringWorks Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd. , GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.